Literature DB >> 27385168

Role of Hepatic Drug Transporters in Drug Development.

Houfu Liu1, Jasminder Sahi2.   

Abstract

Hepatic drug transporters can play an important role in pharmacokinetics and the disposition of therapeutic drugs and endogenous substances. Altered function of hepatic drug transporters due to drug-drug interactions (DDIs), genetic polymorphisms, and disease states can often result in a change in systemic and/or tissue exposure and subsequent pharmacological/toxicological effects of their substrates. Regulatory agencies including the US Food and Drug Administration, European Medicines Agency, and Japan Pharmaceuticals and Medical Devices Agency have issued guidance for industry on drug interaction studies, which contain comprehensive recommendations on in vitro and in vivo study tools and cutoff values to evaluate the DDI potential of new molecular entities mediated by hepatic drug transporters. In this report we summarize the latest regulatory and scientific progress of hepatic drug transporters in clinical DDIs, pharmacogenetics, drug-induced liver injury (DILI), as well as methods for predicting transporter-mediated pharmacokinetics and DDIs.
© 2016, The American College of Clinical Pharmacology.

Entities:  

Keywords:  drug development; drug-drug interactions; hepatic drug transporters; pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 27385168     DOI: 10.1002/jcph.703

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives.

Authors:  Anna Zerdoug; Marc Le Vée; Shotaro Uehara; Béatrice Lopez; Christophe Chesné; Hiroshi Suemizu; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-06       Impact factor: 2.569

2.  Molecular Basis Underlying Hepatobiliary and Renal Excretion of Phenolic Acids of Salvia miltiorrhiza Roots (Danshen).

Authors:  Jun-Lan Lu; Xue-Shan Zeng; Xin Zhou; Jun-Ling Yang; Ling-Ling Ren; Xin-Yu Long; Feng-Qing Wang; Olajide E Olaleye; Nan-Nan Tian; Ya-Xuan Zhu; Jia-Jia Dong; Wei-Wei Jia; Chuan Li
Journal:  Front Pharmacol       Date:  2022-05-10       Impact factor: 5.988

3.  Preclinical Evaluation of [18F]LCATD as a PET Tracer to Study Drug-Drug Interactions Caused by Inhibition of Hepatic Transporters.

Authors:  Andrea Testa; Sergio Dall'Angelo; Marco Mingarelli; Andrea Augello; Lutz Schweiger; Andrew Welch; Charles S Elmore; Dana Dawson; Pradeep Sharma; Matteo Zanda
Journal:  Contrast Media Mol Imaging       Date:  2018-07-30       Impact factor: 3.161

4.  Development and Application of an UHPLC-MS/MS Method for Comparative Pharmacokinetic Study of Eight Major Bioactive Components from Yin Chen Hao Tang in Normal and Acute Liver Injured Rats.

Authors:  Yun Wang; Xinrui Xing; Yan Cao; Liang Zhao; Sen Sun; Yang Chen; Yifeng Chai; Si Chen; Zhenyu Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-01       Impact factor: 2.629

5.  Interindividual Diversity in Expression of Organic Anion Uptake Transporters in Normal and Cirrhotic Human Liver.

Authors:  Tatsuya Taniguchi; Alana Zanetti-Yabur; Pijun Wang; Mykhaylo Usyk; Robert D Burk; Allan W Wolkoff
Journal:  Hepatol Commun       Date:  2020-03-11

6.  Real-time fluorometric evaluation of hepatoblast proliferation in vivo and in vitro using the expression of CYP3A7 coding for human fetus-specific P450.

Authors:  Shota Okuyama; Fumihiko Kawamura; Musashi Kubiura; Saori Tsuji; Mitsuhiko Osaki; Hiroyuki Kugoh; Mitsuo Oshimura; Yasuhiro Kazuki; Masako Tada
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 7.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Authors:  Mohamed Elmeliegy; Manoli Vourvahis; Cen Guo; Diane D Wang
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

Review 8.  In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research.

Authors:  Eneko Madorran; Andraž Stožer; Sebastjan Bevc; Uroš Maver
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

Review 9.  Risk undermined in the bilateral pharmaceutical regulatory system in Taiwan.

Authors:  Hui-Po Wang; Chun-Li Wang
Journal:  J Food Drug Anal       Date:  2018-01-17       Impact factor: 6.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.